athenahealth
Network-model B2B SaaS-plus-services. Per Moody's (18 Jan 2022) athenahealth 'generates the majority of its revenue by charging a percentage of' provider collections — a take-rate, not a per-seat licence, which is why the scribe can be free: anything lifting documented E/M levels or throughput raises the collections base it already earns a percentage of. CEO Bob Segert, 4 Nov 2025: 'We think ambient is a feature, not a business.' Sold to independent practices and small-to-mid systems (strongest at 1-75 physicians), plus an Ambient Notes marketplace embedding third-party scribes (Abridge, Suki, iScribe, Nabla).
Earnings, margins, COGS & capex
A large, sticky, cash-generative ambulatory health-IT franchise carrying LBO leverage and disclosing nothing. The investable facts are the shape: revenue is a percentage of what athenahealth collects for clients, so it is recurring and usage-linked; the base is diffuse independent practices, so single-logo risk is negligible; quality is corroborated by five 2026 Best in KLAS awards. Against that: ~$8.25B of debt raised at 2021 multiples, ~10x opening leverage, no post-2021 disclosure, and an AI strategy that forgoes a revenue line — athenaAmbient gives up a fee the category charges $1,188-$5,000/clinician/yr for, to buy retention and a larger collections base.
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~32¢ is cost of goods and ~58¢ operating expense, leaving ~10¢ of operating profit.
Revenue trend
Margins
below pure SaaS — athenaOne carries human RCM services
unknown; LBO thesis was cost-out plus growth
collections-linked; equity FCF depends on the debt stack
COGS structure
Two pools. (1) Revenue-cycle SERVICES — claims scrubbing, denials, patient billing — delivered substantially offshore: real labour COGS, and why gross margin cannot be assumed at software levels. (2) Platform and AI inference: cloud hosting plus ASR and LLM summarisation for athenaAmbient and Sage. The second is structurally awkward — cost scales with encounters while price is fixed at zero, so every point of attach is margin cost with no matching revenue. The offset is indirect: documentation that raises documented E/M levels or throughput feeds the take-rate automatically — an INFERENCE from the revenue model plus the measured E/M effect, not a disclosed result.
Capex
Asset-light, no owned data centres. What matters is capitalised software development plus AI compute as cloud opex; debt amortisation and interest, not capex, are the dominant claims on cash.
Latest earnings
n/a
None while sponsor-owned. Directional company statements only: '>170,000 providers' (Nov 2025), 'over 160,000 clinicians' reachable via Abridge (Feb 2025), athenaAmbient in user testing from Feb 2026 at no additional cost, Sage copilot in limited release. No attach rate, retention figure or ARR has ever been published.
- Ownership
- Bain Capital + Hellman & Friedman (co-investors incl. GIC, ADIA subsidiary); closed Feb 2022
- Last negotiated mark
- ~$17B enterprise value (Feb 2022), negotiated not clearing; prior mark $5.7B (2018)
- Last named revenue
- ~$1.9B LTM to 30 Sep 2021; $1.22B FY2017 audited
- Funded debt at close
- ~$8.25B ($5.75B 1L TLB + $2.5B notes) + $1.0B delayed-draw + $1.0B revolver
- Opening leverage
- ~10x debt/EBITDA (~11x ex-savings); B3 CFR, Caa2 notes, Jan 2022 — no later action located
- Providers
- 'more than 170,000' (Nov 2025); 'over 160,000 clinicians' (Feb 2025)
- athenaAmbient price
- $0 incremental — 'embedded in the core athenaOne fee and will not be at any incremental charge' (4 Nov 2025)
- KLAS
- Five 2026 Best in KLAS awards (4 Feb 2026)
Growth drivers
- Take-rate economics — revenue is a percentage of client collections, compounding with volume, payer mix and coding completeness without a new sale
- athenaAmbient at no incremental cost as a retention weapon — no second contract, no second business-associate agreement, no second security review
- Five 2026 Best in KLAS awards (4 Feb 2026) — Overall Independent Physician Practice Suite (3rd consecutive year), Ambulatory EHR 11-75 physicians independent (5th), Practice Management 11-75 independent (4th), plus first wins in Ambulatory EHR >75 physicians and Ambulatory Behavioral Health
- Adjacency expansion inside 160,000-170,000+ providers — behavioural health, patient engagement, and the Ambient Notes third-party channel
- ONC's HTI-5 proposed rule (90 FR 60973-60975, 29 Dec 2025) — $0 implementation cost on certified health-IT developers, 34 certification criteria removed and 7 revised, and $1.53B of present-value savings in 2024 dollars at a 7% discount from 2027 in perpetuity — an INDUSTRY-WIDE figure for the certified-developer cohort (Epic, Oracle Health, athenahealth, Meditech, eClinicalWorks), not an athenahealth figure
- CMS-0057-F prior-auth APIs — payer compliance lands 1 Jan 2027 (decision clocks of 7 calendar days standard / 72 hours expedited began 1 Jan 2026)
Bull & bear
The rare AI-era incumbent whose distribution and revenue model point the same way: athenahealth owns the ambulatory workflow surface and earns a percentage of what clients collect, so it does not need to sell the AI feature to be paid for it. Giving athenaAmbient away buys retention across 160,000-170,000+ providers, denies standalone vendors the second contract they need, and routes any documentation-driven collections uplift into a take-rate it already holds.
- The revenue model is the moat: paid on collections it can improve with AI, with no new SKU, procurement or security review
- $0 incremental is strategy, not charity — the same logic that lets Doximity ship Scribe at $0 against pharma's commercial budget
- It wins where it competes: a fifth consecutive Best-in-KLAS Ambulatory EHR win at 11-75 physicians independent, the band Epic historically served worst
- Diffuse customers mean no single-logo churn event can re-rate the business
- Real cash engine: $280-300M of annualised FCF projected post-close on recurring, collections-linked revenue with high switching costs
- Live private bid for this profile: ModMed $5.3B, R1 RCM $8.9B, NextGen $1.8B — sponsor liquidity here has repeatedly cleared
A ~$1.9B-revenue (2021) business carrying ~$8.25B of debt struck at 2021 multiples, silent for five years, now voluntarily forgoing the one new revenue line its category monetises — while the segment it dominates is exactly where Epic is expanding. The strategy that makes athenahealth the most important datapoint on the ambient price ladder also adds cost without revenue, and nobody outside the sponsors can see whether the deleveraging worked.
- Leverage first: ~10x opening debt/EBITDA (~11x ex-savings), B3 CFR with Caa2 unsecured notes, floating-rate debt maturing 15 Feb 2029, no ratings action since Jan 2022
- Zero disclosure means zero verification — a five-year reporting gap in a levered credit is a risk, not a neutral fact
- athenaAmbient is a pure cost line and the collections offset is an inference; the one controlled measurement is a $2,008/yr point estimate the authors call a conservative lower bound that cannot generalise to cost-benefit
- Adoption intensity cuts both ways: only ~32% of JAMA adopters used their scribe on 50%+ of visits, the threshold associated with ~2x the EHR-time and ~3x the documentation-time reduction — which is why the authors call $167.37 conservative for a fully-adopted clinician, and equally why a platform shipping to everyone realises only the population average
- Epic is entering the 1-75-physician band from 43.7% of acute-care hospitals, with AI Charting generally available since 4 Feb 2026
- No instrument, no exit signposted: 4.5 years into a hold entered at a peak-multiple $17B enterprise value. If the multiple regime does not return, the equity absorbs it
What it is worth
No market price and no disclosed financials, so there is no valuation — only a stale negotiated mark and a comparables band. The mark: ~$17B ENTERPRISE value (agreed 22 Nov 2021, closed Feb 2022) = ~8.9x the ~$1.9B LTM revenue Moody's cited (derived), struck at the 2021 multiple peak. A negotiated sponsor-to-sponsor transaction price, NOT a clearing price, ~4.5 years old, and enterprise value — ~$8.25B of funded debt sits inside it, implying a sponsor cheque near $8-9B (derived). No valuation is inferred from any raise, and no current revenue figure exists to build a multiple on.
Epic's down-market expansion takes share at 1-75 physicians, payer downcoding and prior-auth friction compress the collections base the take-rate sits on, athenaAmbient adds inference cost with no measurable collections offset, and a ~10x-levered structure refinances into a worse market before Feb 2029. The equity absorbs it, and nobody outside the sponsors would see it coming.
Revenue grew and leverage came down, but not enough to clear a 2021 peak-multiple entry in a higher-rate regime. The sponsors hold longer, refinance ahead of 15 Feb 2029, and exit at or modestly around the $17B mark — a return from EBITDA growth and debt paydown rather than multiple expansion.
Revenue compounded at the high-single-to-low-teens rate Moody's expected, leverage fell toward the sub-7.5x band, athenaAmbient reaches a published attach rate above half the athenaOne base and demonstrably lifts collections through the take-rate, and the sponsors exit above the $17B mark into a market that already cleared ModMed at $5.3B and R1 at $8.9B.
The comparables band, all private marks with dates: ModMed $5.3B (Mar 2025), R1 RCM $8.9B (Nov 2024), NextGen $1.8B (Nov 2023). Listed anchor: Waystar at ~$4.05B market cap on $1.21B TTM revenue — ~3.3x market-cap-to-revenue at the 31 Jul 2026 close, higher on an EV basis given its debt — at a 42-43% adjusted-EBITDA margin. These bracket what a bidder pays for ambulatory health-IT and RCM cash flows; they do NOT establish a price for athenahealth, whose revenue base is undisclosed. A bidder pays for the collections take-rate, the retention position, and an attach rate high enough to show the free-bundle strategy worked; a bidder discounts five years of non-disclosure, ~$8.25B of debt into a 2029 maturity, services-mix gross margin, and Epic moving down-market. Not investment advice, no price target, no view on any security — athenahealth has none.
SWOT
Strengths
- Take-rate revenue — a percentage of client collections — is recurring, usage-linked, and hard to displace without re-plumbing how the practice gets paid
- Owns the workflow surface: a scribe inside athenaOne needs no second contract, BAA or security review
- Five 2026 Best in KLAS awards, incl. a fifth consecutive Ambulatory EHR win at 11-75 physicians independent
- Diffuse base of 160,000-170,000+ providers — the opposite of the mega-system concentration defining enterprise ambient vendors
- 'Ambient is a feature, not a business' — defensible for a platform owner, corrosive for anyone selling the feature standalone
Weaknesses
- ~$8.25B funded debt and ~10x opening leverage on ~$1.9B revenue, with no post-2021 disclosure showing the expected deleveraging happened
- Total opacity since 2021 — no revenue, margin, attach, retention or leverage figure, so every current valuation statement is an estimate
- Services-carrying gross margin — revenue-cycle work is labour, so it cannot re-rate to software multiples on mix alone
- Forgoes a $1,188-$5,000/clinician/yr category fee while carrying athenaAmbient's inference cost
- Uninvestable as an instrument: no security exists and no exit is signposted
Opportunities
- Convert the free scribe into collections uplift — the only controlled measurement of ambient's revenue effect is $167.37 per adopting clinician per month (95% CI $86.52-$248.21; JAMA 2026;335(16):1408-1417) = $2,008/yr at the point estimate, $1,038-$2,979/yr across the interval — a take-rate owner captures a share wherever clinicians are paid fee-for-service
- Publishing an athenaAmbient attach rate above half the athenaOne base would establish the $0 EHR-native bundle at scale rather than as an announcement
- Prior-authorisation and payer-API workflow ahead of CMS-0057-F's 1 Jan 2027 dates
- HTI-5 also proposes narrowing the information-blocking Manner Exception (45 CFR 171.301) and deleting the TEFCA Manner Exception (45 CFR 171.403) — both PROPOSED, not final
- Sponsor exit into a market that keeps paying for this class — ModMed at a $5.3B valuation (Mar 2025), R1 RCM at $8.9B (Nov 2024), NextGen at $1.8B (Nov 2023)
Threats
- Epic moving down-market — per KLAS via trade press, Epic held 43.7% of US acute-care hospitals in 2025 (from 42.3%, a fifth consecutive year of gains) and 56.9% of beds, with KLAS flagging expansion among small health systems — athenahealth's band. AI Charting reached general availability 4 Feb 2026, licensed inside the EHR relationship at an UNDISCLOSED price
- Epic's absolute-dollar asymmetry — the ~$1.0B of revenue it added in 2025 alone (+17.5%, an estimate divided by an estimate) is a large fraction of athenahealth's whole base
- Floating-rate leverage into a 15 Feb 2029 maturity, with no post-2021 ratings action confirming the credit improved through a higher-rate regime
- The measured value of what athenahealth gives away is small versus list prices — and the authors call it a conservative LOWER bound whose analysis 'cannot generalize to cost-benefit considerations', monetising billed E/M visits only at the 2025 MPFS
- The E/M coding channel is worth ~$0 outside fee-for-service (Kaiser, the VA, staff-model plans, full-risk MA/ACO), while payers contest the commercial channel and CMS's statutory MA coding-intensity adjustment claws back mechanically
Moats, dependencies & bottlenecks
Moats
Percentage-of-collections revenue tied to the practice's money path Displacing athenahealth means re-plumbing how the practice gets paid, not swapping a UI — and it is paid on any AI that raises documented acuity or throughput without pricing it.
Strong at 1-75 physicians High once deployed, contested at the top of the range The bottleneck the board turns on: every clinical AI must render into the record, and the record owner controls integration depth, data egress and bundling.
Strong as a weapon, negative as a P&L line a strategy, reversible at general availability One of only two confirmed genuinely free rungs, with Doximity Scribe at $0 = 0x. Epic's AI Charting is licensed inside the EHR relationship at an undisclosed price and must NOT be called free.
ONC certification, clearinghouse connections and the information-blocking / TEFCA regime are a fixed cost a new entrant pays in full.
A five-year Best-in-KLAS run at 11-75 physicians independent. Small practices have the least capacity to migrate — sticky, but the most price-sensitive.
Dependencies
GIC, an ADIA subsidiary) Capital structure and strategic control Set leverage tolerance, cost-out, reinvestment and the exit clock. No exit or re-listing signposted; the equity is unownable by outsiders.
Financing / refinancing ~$8.25B funded at close, floating-rate first-lien term debt maturing 15 Feb 2029, Caa2 unsecured notes; no post-2021 ratings action located.
Take-rate revenue moves with what clients collect, so payer downcoding, prior-auth friction and any shift to capitation compress it.
Regulatory / reimbursement MPFS rates price every documented E/M visit; a CY2028 MPFS -2.5% efficiency adjustment extended to E/M would trim the measured ambient uplift by ~$4.18/clinician/month (to ~$163.19) — not enough to eliminate it.
Suki, iScribe, Nabla; undisclosed speech/LLM providers) Marketplace partners that are also substitutes; core technology and variable COGS athenahealth is both Abridge's ambulatory channel (25 Feb 2025, reaching 'over 160,000 clinicians') and, via athenaAmbient at $0, the sharpest price attack on Abridge's ~$2,500/clinician/yr reported list price (no primary source — Abridge publishes no pricing).
Advantages
- Only confirmed zero-incremental-fee EHR-native ambient bundle — a price anchor no standalone ambulatory vendor can match
- Revenue is a percentage of client collections, so AI that improves documentation pays athenahealth without being priced
- Deepest quality validation in its actual buying segment (five 2026 Best in KLAS awards)
- Diffuse base of 160,000-170,000+ providers — negligible single-logo concentration
- Certified-developer status turns the ONC/TEFCA compliance estate into a barrier rather than a cost
Weaknesses
- ~$8.25B funded debt and ~10x opening leverage, with no post-2021 disclosure to verify deleveraging
- Zero financial transparency since 2021 at any source
- Forgoes the $1,188-$5,000/clinician/yr ambient revenue line while carrying its cost
- Weak-to-absent in acute care, where Epic holds 43.7% of hospitals and 56.9% of beds
- No security and no signposted exit: uninvestable at 6 August 2026
Bottlenecks
- Debt service and the 15 Feb 2029 maturity — cash is claimed by the capital structure before it reaches strategy
- Ambient inference cost scaling with encounters while price stays fixed at zero incremental
- athenaAmbient still in user testing (entered Feb 2026) rather than confirmed general availability; no attach rate published
- Services-heavy revenue-cycle delivery caps gross margin and ties capacity to headcount
- Documentation accuracy and record-integrity liability. No FDA 510(k) clearance, De Novo authorisation or PMA approval is claimed for athenaAmbient or Sage, and none is implied — the ambient evidence base is time-and-revenue, not clinical efficacy
Top signals & trends
Top signals
bullish for athenahealth, bearish for standalone ambient · The only confirmed zero-incremental-fee EHR-native bundle; it re-addresses the ambient dollar to the record owner rather than destroying it.
neutral / pending · General availability IS the test and the explicit falsifier: a per-clinician fee at GA removes the only confirmed free EHR-native rung.
Independent corroboration of retention-relevant quality in the exact band Epic is expanding into.
The same bundling logic executed by a larger record owner moving into athenahealth's tier.
bearish for the standalone vendor · Abridge's ~$2,500/clinician/yr reported list price (no primary source — Abridge publishes no pricing) = 1.24x the $2,008/yr point estimate (0.84-2.41x across the interval). Competing with a $0 in-product default is a pricing problem, not a product problem.
bearish (unverifiable) · Four and a half years of silence on a ~10x-levered credit through a higher-rate regime.
Trends
positive for athenahealth, negative for standalone vendors · ~60 ambient scribes on the market per PHTI (March 2025) against ~$600M of US ambient-scribe revenue in 2025 (Microsoft/Nuance 33%, Abridge 30%, Ambience 13%, Suki 10%, Freed 4%, Nabla 4%, other 7%).
negative for the category, neutral for athenahealth · Enterprise-tier reported list prices — no primary source, since no ambient vendor publishes a price list — run 1.24-2.49x the $2,008/yr point estimate and 0.84-4.82x carrying the 95% interval; only Suki and the Ambience full suite sit above value at every point. 'Priced above measured value' is the central case, not a settled one — and a $0 rung is unaffected.
$3-6B/yr is a framing range from today's list prices; ~$1.0-1.2B/yr is the bottom-up terminal pool from measured value (~1.0-1.2M addressable ambulatory clinicians at ~$1,000/yr). ~$600M was already booked in 2025, with the rest to be won against $0.
Cigna's R49 auto-downcoding policy (one-level reduction of 99204-05 / 99214-15 / 99244-45, scheduled 1 Oct 2025) was paused; Maryland fined Cigna $80,000 on 13 Mar 2026 and extended the prohibition statewide via Bulletin 26-9 (7 Apr 2026). The audit right is untouched.
Epic at 43.7% of acute-care hospitals and 56.9% of beds in 2025; Oracle Health 21.9% and a third consecutive year as largest net share loser (-56 hospitals, -14,676 beds), per KLAS via trade press.
HTI-5 (proposed 29 Dec 2025) would cut 34 certification criteria at $0 implementation cost to certified developers while CMS-0057-F puts payer prior-auth APIs on a 1 Jan 2027 clock.
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
ASR plus LLM summarisation per encounter for athenaAmbient and Sage; vendors undisclosed. Opex that falls with token prices.
Multi-tenant hosting for athenaOne; provider not disclosed, no owned data-centre programme.
India-based claims scrubbing, denials and billing — the labour keeping gross margin below software levels.
Claims, eligibility and remittance connections to commercial payers, Medicare and Medicaid — the plumbing the take-rate runs on.
The 2029 first-lien term loan and Caa2 notes price the refinancing and, ultimately, equity returns.
Independent physician practices (1-75 providers) The core segment: Best in KLAS for Ambulatory EHR and Practice Management at 11-75 physicians independent, a fifth and fourth consecutive year.
First Best in KLAS Ambulatory EHR award above 75 physicians in 2026 — evidence of upmarket movement.
The tier the Abridge integration targeted (Feb 2025), and the tier KLAS says Epic is now entering.
athenaOne for Behavioral Health won Best in KLAS in its first eligible year (2026).
'Over 160,000 clinicians' (Feb 2025) and 'more than 170,000 providers' (Nov 2025), both company-stated.
The structural competitor: 43.7% of acute-care hospitals and 56.9% of beds in 2025 per KLAS via trade press, expanding among small health systems. Revenue $4.9B (2023) / $5.7B (2024) / $6.7B (2025), company-stated to Becker's 28 Apr 2026, unaudited — Epic files nothing, no margin knowable. Un-ownable: no equity instrument exists.
Closest like-for-like substitute in the independent tier — same EHR+PM+RCM bundle, large ambulatory base. Published ambulatory share estimates for this tier conflict widely; none is asserted here.
Oracle FY2026 revenue $67.4B (+17%); Oracle Health holds 21.9% of acute-care hospitals, lost 56 hospitals / 14,676 beds in 2025, and Millennium was the lowest-scoring acute EHR in 2026 Best in KLAS — displacement opportunity as much as threat.
Direct specialty-ambulatory competitor running the same sponsor leverage-and-cost-out playbook.
Specialty-first ambulatory EHR; the freshest private valuation datapoint in ambulatory health IT.
Legacy ambulatory base plus a data business, delisted after failing to complete financial reporting, in a strategic-alternatives process since May 2024 — displaceable accounts more than a threat.
Competes on the revenue-cycle half of the bundle at enterprise scale (500+ organisations, 93 of the top 100 health systems, >$1T of net patient revenue managed, per company).
The listed RCM comparable and the only visible margin profile on this money path: $21.11 at the 31 Jul 2026 close, ~$4.05B market cap, Q2-2026 revenue $319.7M (+18%), FY2025 adjusted-EBITDA margin 42.04%, TTM revenue $1.21B at 68-69% gross margin.
~33% of the ambient category and 100,000+ clinicians daily at a $369-$604 per-provider-per-month list; trade-reported as rolling out inside Ambient Notes. The whole contested US ambient pool is under 2% of Microsoft's $331.8B FY2026 revenue (1.81% at the top of the range).
Partner and rival: joined Ambient Notes 25 Feb 2025 reaching 'over 160,000 clinicians', while athenaAmbient at $0 attacks its ~$2,500/clinician/yr reported list price (no primary source — Abridge publishes no pricing). ~$1.06B raised (a sum the board computes from Abridge's own round announcements plus the reported April 2026 extension, not a figure any source states) on a $5.3B post-money mark from the June 2025 Series E — fourteen months old at 6 August 2026; the April 2026 $316M extension came at a price no source discloses.
The other confirmed $0 rung — Scribe free to every verified US clinician, funded by pharma's commercial budget. $20.91 at the 31 Jul 2026 close, ~$3.76B market cap, FY2026 revenue $644.9M (+13%) at an 89.1% GAAP gross margin.